产品说明书

LIT-927

Print
Chemical Structure| 2172879-52-4 同义名 : -
CAS号 : 2172879-52-4
货号 : A914195
分子式 : C17H13ClN2O3
纯度 : 98%
分子量 : 328.75
MDL号 : MFCD31726172
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 12 mg/mL(36.5 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 The chemokine receptor CXCR4 and its ligand CXCL12 are involved in the progression and dissemination of a diverse number of solid and hematological malignancies. Binding CXCL12 to CXCR4 activates a variety of intracellular signal transduction pathways that regulate cell chemotaxis, adhesion, survival, proliferation, and apoptosis[1]. LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[2]. LIT-927 is selected as lead neutraligand and characterized its activity (IC50) in vivo in a dose–response efficacy study on eosinophil recruitment in mouse model. LIT-927 at 10 μM is able to inhibit the increase in intracellular calcium concentration in EGFP-CXCR4+ HEK cells in response to CXCL12, while it has no effect on calcium responses triggered by either CCL17 or CCL22 on EGFP-CXCR4+ HEK cells, CCL5 on EGFP-CCR5+ HEK cells, or CCL2 on EGFP-CCR2+ HEK cells. These results demonstrate the high selectivity of LIT-927 toward CXCL12 vs other chemokines also involved in asthma[2]. More interestingly, LIT-927 displayed very good to excellent in vivo activity, inhibiting eosinophil infiltration by 48%[2]. LIT-927 reduced eosinophil recruitment in a murine model of allergic airway hypereosinophilia, LIT-927 was the only one to display inhibitory activity following oral administration[2].
作用机制 Docking of LIT-927 to this pocket at the vicinity of Trp57 is possible at the condition to allow side-chain flexibility for three residues (Arg20, Trp57, and Tyr61) that would control the entry to the Trp57 pocket.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.21mL

3.04mL

1.52mL

30.42mL

6.08mL

3.04mL

参考文献

[1]Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39(3):282-92. doi: 10.1016/j.exphem.2010.11.010. Epub 2010 Dec 5. PMID: 21138752.

[2]Regenass P, Abboud D, Daubeuf F, Lehalle C, Gizzi P, Riché S, Hachet-Haas M, Rohmer F, Gasparik V, Boeglin D, Haiech J, Knehans T, Rognan D, Heissler D, Marsol C, Villa P, Galzi JL, Hibert M, Frossard N, Bonnet D. Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia. J Med Chem. 2018 Sep 13;61(17):7671-7686. doi: 10.1021/acs.jmedchem.8b00657. Epub 2018 Aug 28. PMID: 30106292.